EMCDDA

Latest news Noticeboard Inside emcdda.europa.eu Data— all of the latest data and statistics on the drug situation Countries —national and country-specific information Topics (A-Z) —information and resources organised by topic Our activities — information on the EMCDDA's ongoing scientific work and projects Best practice portal — what works in different areas of drug-related interventions Publications — all of the EMCDDA's publications at your fingertips News and events — the latest news and an overview of key events in the drugs calendar About — information about the EMCDDA and its activities

01/11/2018 04:08 PM
Events

Events

Each year, the EMCDDA is involved in organising, hosting, sponsoring or presenting at hundreds of drug-related events including international conferences and technical and scientific meetings. You can find information about these events here. 

The EMCDDA organises each year a number of expert meetings on technical or drug-related topics — the pages below provide further information on these meetings.

You can find below a calendar of drug-related events around the world, including conferences, exhibitions, visits to the EMCDDA and internal meetings. New events are added as information becomes available.


06/06/2017 10:17 AM
Data

 


05/19/2017 12:31 PM
Best practice

Best practice portal

Discover what works (and what doesn't work) in the areas of drug prevention, treatment, harm reduction and social reintegration.

Keywords

Use the keywords below to help you find best practice information for a specific topic. Clicking on a keyword will modify the available selection on the left. To remove a keyword filter, just click on it again.

Substance: alcohol amphetamines cannabis cocaine new psychoactive substances (NPS) presecription medicines opioids tobacco

Specific target groups or settings: partygoers/nightlife pregnant women prison young people

Desired outcome: improve education improve employability prevent crime reduce mortality reduce risky behaviours reduce risky driving reduce substance use retain in treatment prevent risky injecting prevent infectious diseases

Explore all resources in the Best practice portal

Frequently asked questions

Frequently asked questions

We have put together a list of frequently asked questions from professionals and others working in the field. All answers link to a best practice answer sheet where you can find additional information.

Prevention for families

Prevention programmes can be delivered to families, with or without any prior screening for vulnerability. Vulnerable families are here considered as families where one or more members misuse alcohol and/or drugs, and/or families with high levels of parental conflict and violence where personal relationships are poor.

thumbs up symbol What works?

  • green tick mark Involving the whole family in prevention activities helps reduce the use of alcohol, tobacco and drugs
  • green tick mark Collaboration between parents and teachers supports smoking cessation
  • green tick mark Moreover, home visits for disadvantaged families reduce alcohol and cigarette consumption

question mark symbol What's unclear?

  • It is not clear why interventions focusing only on one dimension (for example only schools or only training for parents) are less helpful to reduce substance use in young people

thumbs down symbol What doesn't work?

  • We are not aware of any family interventions that cause harm

Prevention for school students

Prevention targeting schools offers a systematic and efficient way of reaching large numbers of young people.

thumbs up symbol What works?

  • green tick mark Multicomponent interventions delivered at school and based on social influence and/or on learning social skills are helpful for reducing alcohol and drug use, especially cannabis
  • green tick mark Moreover, interactive interventions targeted at problem students help reduce substance use and ‘drink-driving’ behaviour
  • green tick mark In addition, peer-led interventions reduce illicit substance use
  • green tick mark School-based programmes help to reduce bullying and victimisation, both behaviours that can be associated with substance use

question mark symbol What's unclear?

  • It is still unclear if school-based brief interventions can help to reduce substance use or improve behaviour in young people. School-based brief interventions showed no difference when compared with just the provision of information, yet when compared with no intervention at all, they showed weak evidence of reducing cannabis use
  • We cannot say if ‘booster sessions’ are really helpful in reinforcing the main messages of school-based prevention programmes
  • Interventions that teach social skills might not be helpful in discouraging hard drug use in students
  • In addition, programmes focused only on peers and those that just provide information  might not reduce alcohol and tobacco use

thumbs down symbol What doesn't work?

  • We are not aware of any school-based interventions that cause harm

Prevention for communities

Community here is understood to mean a group of individuals sharing a common geographical and administrative setting. Interventions within a community do not necessarily address all of the community concerned but may involve several key actors (for example health services, schools and sport facilities).

thumbs up symbol What works?

  • green tick mark Multicomponent and interactive interventions delivered in the community reduce drug, tobacco and alcohol use in high-risk youths
  • green tick mark Furthermore, community support groups, involving also other family members, help young people living in problem families
  • green tick mark Mentoring programmes reduce alcohol use in young people
  • green tick mark Computer-based programmes have the potential to reduce drug use when targeted at illicit recreational drug users, at least in the medium term

question mark symbol What's unclear?

  • It is not clear if programmes focused only on one component or mentoring programmes are helpful in reducing alcohol as well as drug use
  • More generally, it is not clear whether anti-alcohol and anti-cannabis community interventions reduce consumption
  • It is not clear if positive youth development (PYD) interventions, i.e. programmes that favour the promotion of positive assets over traditional risk reduction, are helpful in reducing alcohol as well as drug use

thumbs down symbol What doesn't work?

  • We are not aware of any community interventions that cause harm

Prevention for partygoers

The use of both new and more traditional substances occurs in people taking part in entertainment and recreational settings. Preventive interventions aim to protect the safety of these people in relation to car accidents, violence and risky behaviours.

thumbs up symbol What works?

  • green tick mark Multicomponent interventions involving the community reduce car accidents, public nuisance and crime related to alcohol consumption
  • green tick mark Programmes targeting ‘drink-driving’ and media campaigns reduce car accidents, including fatal crashes
  • green tick mark Police supervision in venues and their immediate surroundings reduces public disorder while training staff serving alcohol in ‘responsible serving’ reduces clients’ alcohol consumption and intoxication levels

question mark symbol What's unclear?

  • It is not clear if designated driving programmes (when one person in a group is designated to remain sober for the night and drive the others home) reduce drink-driving harms
  • Also it is not clear if drink-driving programmes discourage people from travelling in a car with an intoxicated driver and if the promotion of responsible drinking can change alcohol consumption
  • It is not clear if interlocks mechanisms (automatic mechanisms that lock a car’s engine, preventing it from starting) reduce driving under the influence of alcohol in the long term
  • We do not yet know if restricted opening hours can reduce alcohol-related injuries and if programmes involving police and law enforcement measures can control and reduce alcohol sales

thumbs down symbol What doesn't work?

  • Information provision does not prevent drug- and alcohol-related problems and educational interventions do not influence attitudes and drinking behaviour
  • Electronic Age Verification (EAV) devices do not help increase the frequency of age verification at recreational premises

Prevention for the general population

Typical interventions aimed at the general population are media campaigns and other interventions that target everyone (for example taxation and laws).

thumbs up symbol What works?

  • green tick mark Mass-media campaigns associated with other interventions, both school-based and/or community-based, can help reduce tobacco use
  • green tick mark They also reduce car accidents and drink-driving behaviours
  • green tick mark Computer-based programmes have the potential to reduce recreational drug use in universal drug prevention programmes, at least in the medium term

question mark symbol What's unclear?

  • It is not clear if mass media campaigns can change behaviours related to illicit drug use

thumbs down symbol What doesn't work?

  • Mass-media campaigns as standalone interventions (without any other component) do not reduce tobacco and alcohol consumption

Treatment for amphetamine users

Amphetamine dependence is associated with compulsive behaviours, chronic and episodic usage, and development of tolerance and thus a substantial rise in doses.

thumbs up symbol What works?

  • green tick mark Some of the drugs used to treat depression (fluoxetine and imipramine) can help amphetamine users stay in treatment in the short and medium term
  • green tick mark For pregnant women, medications to assist detoxification from stimulants can be used but should be reserved when specific symptoms emerge

question mark symbol What's unclear?

  • There are no data supporting a single treatment approach that can tackle the multidimensional facets of amphetamine addiction patterns

thumbs down symbol What doesn't work?

  • Pharmacotherapies based on psychostimulants are probably of little value in the treatment of amphetamine dependence
  • Pharmacotherapy for routine treatment of dependent pregnant women is not recommended

Treatment for cannabis users

Problem cannabis use can lead to difficulties performing at work and legal problems; cannabis dependence has been associated with adverse psychological and physical consequences.

thumbs up symbol What works?

  • green tick mark Any behavioural intervention (including cognitive behavioural therapy (CBT), motivational interviewing (MI) and contingency management) can help to reduce use and improve psychosocial functioning, both in adults and adolescents, at least in the short-term
  • green tick mark Multidimensional family therapy helps reduce use and keep patients in treatment, especially in high-severity young patients
  • green tick markWeb- and computer-based interventions can be effective in reducing cannabis use, at least in the short term

question mark symbol What's unclear?

  • Medical preparations containing THC seem of potential value but given the limited evidence these applications should be considered still experimental

thumbs down symbol What doesn't work?

  • Pharmacotherapies based on antidepressants, anxiolytics and anticonvulsant are probably of little value in the treatment of cannabis dependence
  • Pharmacotherapy for routine treatment of dependent pregnant women is not recommended

Treatment for cocaine users

Problem cocaine use and cocaine dependence can lead to numerous adverse psychological and physical consequences.

thumbs up symbol What works?

  • green tick mark Psychosocial interventions can help to reduce cocaine use by influencing the mental processes and the behaviours related to the addiction
  • green tick mark Medicines used to treat other diseases (such as disulfiram for alcohol addiction, antidepressants and antiparkinsonians) can help cocaine users to reduce use
  • green tick mark Various psycho-social treatment (including contingency management) interventions for crack abuse/dependence show some positive yet also some limited/short-term efficacy
  • green tick mark For pregnant women, medications to assist detoxification from stimulants can be used but should be reserved when specific symptoms emerge. Psychosocial interventions alone or in addition to the usual care do not make a difference in both treatment and obstetrical outcomes, when standard comprehensive care options are in place, eg prenatal care, counselling

question mark symbol What's unclear?

  • It is not clear whether antidepressants help reduce the craving for cocaine
  • It is also not clear if psycho-stimulants can help treat cocaine dependence

thumbs down symbol What doesn't work?

  • Pharmacotherapies based on dopamine agonists, anticonvulsants as well as antipsychotics are probably of little value in the treatment of cocaine dependence
  • Pharmacotherapy for routine treatment of dependent pregnant women is not recommended

Treatment for opioid users

Opioid dependence is the illicit drug related condition for which we have the strongest evidence of what works and what does not.

thumbs up symbol What works?

  • green tick mark Opioid substitution treatment, combined with psychosocial support, helps patients stay in treatment and reduces use and mortality. It also has a positive impact on the mental health of patients
  • green tick mark Methadone and buprenorphine are the recommended pharmacological treatments. Taking into account clinical practice, methadone is superior to buprenorphine in retaining people in treatment – particularly in the first weeks - and equally suppresses illicit opioid use
  • green tick mark Heroin-assisted treatment is recommended in adult chronic opioid users who failed previous methadone treatment attempts
  • green tick mark Opioid substitution treatment is also strongly recommended for pregnant women dependent on opioids, even more than attempting dexotification. Psychosocial interventions alone or in addition to the usual care do not make a difference in both treatment and obstetrical outcomes, when standard comprehensive care options are in place, eg substitution treatment, prenatal care, counselling
  • green tick mark When detoxification is indicated, methadone or buprenorphine at tapered dosages are used in association with psychosocial interventions. Detoxification with alpha2-adrenergic agonists (eg. Clonidine and similar medications) is also effective, but there are fewer adverse effects with methadone
  • green tick mark Relapse prevention is supported by naltrexone when relapse has major practical implications (for example professionals who risk losing their job or prisoners on probation)
  • green tick markMethadone or buprenorphine are equally effective for treatment of patients dependent on pharmaceutical opioids

question mark symbol What's unclear?

  • It not clear which option (methadone or buprenorphine) is the best choice in order to avoid drop-out when treating pregnant women
  • It is not clear if the opioid antagonist naltrexone, normally used to prevent relapse to use, works for long-term treatment
  • For detoxification, it is unclear if detoxification under minimal sedation can help users to complete treatment and avoid relapse
  • It is also unclear what helps more between detoxification or substitution treatment to reduce use when dealing with adolescents

thumbs down symbol What doesn't work?

  • Detoxification under heavy sedation does not work and can actually be harmful

What is unclear?

  • It is not clear why interventions focusing only on one dimension (for example only schools or only training for parents) are less helpful to reduce substance use in young people

What does not work?

  • We are not aware of any family interventions that cause harm in terms of increased drug use

Harm reduction for opioid injectors

Historically, harm reduction strategies were initiated to address the risks of contracting infectious diseases (namely HIV) among injecting drug users. The majority of evidence-supported interventions still address this target group.

thumbs up symbol What works?

  • green tick mark Infections caused by HIV and Hepatitis C among people who inject opioids can be prevented with opioid substitution treatment and the provision of clean needles and syringes
  • green tick mark People have less risky behaviours when they are in opioid substitution treatment, i.e. they inject less, and even when they continue to inject drugs they take less risks when participating in a needle and syringe programme, participate in outreach and education programmes as well as injecting in drug consumption rooms
  • green tick mark Death among drug users is reduced by keeping them in opioid substitution treatment.
  • green tick mark Hepatitis C treatment is effective in active drug users and opioid substitution treatment is not a contraindication to the treatment
  • green tick mark There is some evidence that education and training interventions with take-home naloxone provision decrease overdose-related deaths
  • green tick mark Intranasal administration of naloxone appears to be effective in treatment of opioid overdose when naloxone injection is not possible
  • green tick mark There is also some evidence that safer environment interventions (i.e. syringe exchange programmes, peer-based interventions and drug consumption rooms) help to reach, stay in contact and foster safer environments for highly marginalised target populations
  • green tick markPre-exposure prophylaxis (PreP) of HIV in adults at high risk is effective in reducing HIV acquisition in high-risk people who are HIV-negative. However, issues relating to uptake, adherence, sexual behaviour, drug resistance, prioritisation for prophylaxis and cost-effectiveness are also important to consider, especially at a population level.

question mark symbol What's unclear?

  • Is not clear if being in opioid substitution treatment can help patients adhere better to Hepatitis C treatment or achieve better results
  • It is also unclear whether drug consumption rooms can reduce HIV and Hepatitis C infections

thumbs down symbol What doesn't work?

  • We are not aware of interventions for injecting opioid users that cause harm

Harm reduction for stimulant injectors

The risks for people who inject stimulants differ from those of opioid injectors, mainly because the former tend to inject more times during a day (therefore needle and syringe exchange programmes need to be implemented differently).

thumbs up symbol What works?

  • green tick mark Outreach treatment programmes help stimulant injectors to reduce medical problems, such as skin infections

question mark symbol What's unclear?

  • It is not clear if provision of large volumes of sterile injection equipment (in general, stimulant injectors inject more often than opioid users, thus need more syringes), provision of condoms, outreach activities focusing on injecting and risky sexual behaviours can help stimulant injectors
  • It is not clear if injection kits adapted to local drug use patterns, such as for people that inject home-made stimulants (e.g. distribution of specific paraphernalia for the production of drugs), can help to reduce harms
  • It is not clear if dissemination of information on how to inject safely, basic hygiene (hand washing, short nails), vein care and simple wound care as well as distribution of antibacterial creams and ointments can help to reduce harms

thumbs down symbol What doesn't work?

  • We are not aware of interventions for stimulant injectors that cause harm

Harm reduction for non-injectors

Drugs can be taken by inhaling the vapour of a heated substance (chasing), spraying a dissolved substance into the nose, snorting a drug in powder form, or smoking. Each route of administration has specific associated risks.

thumbs up symbol What works?

  • green tick mark Interventions including, for example, the distribution of clean crack kits to prevent people sharing crack pipes, personal vaporisors for cannabis users, information, education and communication material and outreach activities may help these users, however more research is needed

question mark symbol What's unclear?

  • No interventions in this category

thumbs down symbol What doesn't work?

  • We are not aware of interventions for non-injectors drug users that cause harm

Social reintegration — drug treatment

Interventions aimed at the social reintegration of drug users can be provided in the early stages of treatment.

thumbs up symbol What works?

  • green tick mark Providing drug users with an incentive-based treatment (for example contingency management) together with some employment helps them to improve their social condition
  • green tick mark Residential treatment and therapeutic workplaces associated with contingency management improve work attendance and performance

question mark symbol What's unclear?

  • It is not clear if both residential treatment and therapeutic workplaces can specifically help pregnant women improve their employability
  • Moreover, it is also unclear whether therapeutic workplaces associated with training under simulated work conditions can help improve work attendance of drug users in treatment
  • It is not clear if occupation-based interventions help to improve recovery outcomes

thumbs down symbol What doesn't work?

  • So far, we are not aware of interventions which proved to cause harm

Social reintegration — criminal justice

Interventions in the criminal justice system can help to reduce re-offending and thus indirectly increase the employability of individuals, preventing homelessness and the disruption of families and other social networks.

thumbs up symbol What works?

  • green tick mark Drug court programmes (as assessed in the United States which is where most drug courts exist and where the vast majority of studies have been conducted) can help people be independent from financial assistance and find employment or enroll in education

question mark symbol What's unclear?

  • It is not clear if drug court programmes have a more direct impact on the employability of drug users, namely by increasing their employment rate and individual annual income
  • Furthermore, it is unclear whether drug court vocational training programmes reduce reoffending

thumbs down symbol What doesn't work?

  • So far, we are not aware of interventions that proved to cause harm

Social reintegration — housing

Housing support services provide drug users with short- or long-term accommodation, as well as access to other services such as medical care, drug treatment, social activities, education and training.

thumbs up symbol What works?

  • green tick mark Housing interventions to help the employability of drug users should be investigated further

question mark symbol What's unclear?

  • It is not clear if psycho-social treatment interventions can help crack-cocaine users to improve their housing conditions

thumbs down symbol What doesn't work?

  • So far, we are not aware of interventions that proved to cause harm

Social reintegration — education and vocational programmes

The learning or upgrading of literacy or numeracy skills (education) and vocational training to enhance employability, along with practical help, can help drug users in the process of social reintegration.

thumbs up symbol What works?

  • green tick mark Vocational training aimed at developing specific skills and job-seeking skills helps drug users to find employment
  • green tick mark Interventions based on motivational behavioural reinforcement can help methadone maintenance clients find employment

question mark symbol What's unclear?

  • Several ‘training and employment’ programmes have been implemented in the United States yet it is not clear if they can really help improve drug users’ employment motivation and outcomes
  • Furthermore, it is unclear whether drug court vocational training programmes reduce reoffending

thumbs down symbol What doesn't work?

  • Employment counselling does not help drug users in treatment find a full-time job

Social reintegration — employment

Special interventions can provide support for those who have found a job, as well as employment opportunities for those who are struggling to secure work in the open labour market, thereby also addressing other potential barriers, such as low self-confidence.

thumbs up symbol What works?

  • green tick mark Employee assistance programmes help drug users improve work performance
  • green tick mark Supported employment interventions help drug users with mental problems to get a job

question mark symbol What's unclear?

  • It is not clear if psycho-social treatment interventions can help crack-cocaine users to improve their employment conditions

thumbs down symbol What doesn't work?

  • So far, we are not aware of interventions that proved to cause harm

New psychoactive drugs

A new psychoactive substance (or NPS) is a narcotic or psychotropic drug that is not controlled by existing international conventions but that may pose a significant public health threat.

thumbs up symbol What works?

New psychoactive substances are an emerging topic. Research is ongoing in this area and we currently lack evidence on what works best.

  • green tick mark Generally, prevention interventions which stress skills and coping strategies are effective, independently of the substance concerned
  • green tick mark Harm reduction strategies in nightlife settings which have proved to be effective for alcohol may also be effective for new psychoactive substances

question mark symbol What's unclear?

Many research gaps still need to be filled in order to inform future policy responses to new psychoactive substances (Ferri et al., 2014):

  • A comprehensive insight on the scale and patterns of new psychoactive substance use
  • A better understanding of the new psychoactive substances market
  • Research into the short- and long-term consequences of new psychoactive substance use
  • Evidence of specific and/or appropriate treatment options for new psychoactive substance users
  • Outcome evaluations of current interventions and consideration of possible new approaches

thumbs down symbol What doesn't work?

  • New psychoactive substances are an emerging topic. Research is ongoing in this area and we currently lack evidence on what works best.

What can we do in the meantime?

Until today, at both European and international level countries have responded to the problem through consumer protection and law enforcement measures and namely with a range of different innovative legal responses.

Demand reduction initiatives are currently being implemented in Europe (e.g. specialist clinics for users of club drugs in the UK), yet we will need to wait for outcome evaluations of such initiatives before promoting them as European best practice. Standards for drug prevention interventions in recreational settings already exist and can be used as a reference point for new psychoactive substance prevention programmes.

Useful links

  1. Guidance on the clinical management of acute and chronic harms of club drugs and novel psychoactive substance - NEPTUNE Project (2015)
  2. 'Health responses to new psychoactive substances', EMCDDA Perspectives on drugs (2016)
  3. Euro-DEN project - Guidelines on when to call the Emergency Services 112 for unwell recreational drug users
  4. Evidence review — New Psychoactive Substances – Evidence Review (2014), Scottish Government Social Research

Prescription medicines

The EMCDDA defines misuse of medicines the use of a psychoactive medicine with or without a prescription from an appropriate practitioner, clearly outside of accepted medical practice or guidelines, for either self-medication, recreational or enhancement purposes, including in the context of poly drug use.

thumbs up symbol What works?

  • green tick mark Cognitive behavioural therapy helps to reduce benzodiazepines use when added to tapering dosages in the short term as this is not sustained at 6 months follow-up
  • green tick mark Tailored letters sent by GPs to patients, standardised interview with GPs plus tapered doses and relaxation techniques are promising results of three small studies that deserve further investigation

question mark symbol What's unclear?

  • It is not clear if motivational interviewing helps to reduce benzodiazepine use

thumbs down symbol What doesn't work?

  • So far, we are not aware of interventions which proved to cause harm

Prison

Prisons are one of the most important settings to provide interventions aimed at drug users, both in terms of treatment and harm reduction.

thumbs up symbol What works?

  • green tick mark Opioid substitution treatment has a very strong protective factor against death in prison for opioid-dependent prisoners. This is also very important when drug users are released from prison and they need to find continuity of treatment in the community
  • green tick markSubstitution treatment is also particularly important in prison as it reduces injecting risk behaviours
  • green tick markPsychosocial treatments reduce the re-incarceration rates in female drug-using offenders
  • green tick markFor drug-using offenders the use of naltrexone seems to help to reduce their re-incarceration rates
  • green tick markEducation and training interventions with take-home naloxone provision help to decrease overdose-related deaths after release from prison
     

question mark symbol What's unclear?

  • It is unclear if pharmacological treatment can help drug-using offenders to reduce use and criminal activity. Studies results are showing this also for the specific sub-group of female drug-using offenders, yet caution should be taken as the conclusions are based on a small number of trials.
  • Moreover, it is unclear if the provision of needles and syringes in prison help prevent infections and reduce risky behaviours

thumbs down symbol What doesn't work?

  • So far, we are not aware of interventions which proved to cause harm

02/26/2016 12:15 PM
Our activities

Our activities — ongoing projects and programmes

Assessing the many facets of the drug situation in Europe is a challenging task and a wide variety of methods and tools are employed by the EMCDDA in order to do this. Existing tools are being continously refined and improved, and new tools are developed as needs arise. The links below point to the main resources on the EMCDDA website which present methodological information. It should be noted that the categorisation used below is somewhat artificial as there is in fact some overlap between categories.


02/17/2016 09:01 AM
News

New EMCDDA insights into naloxone, the overdose antidote that can help save lives

(Lisbon, 18.01.2016) Between 6 000 and 8 000 drug-induced deaths are reported in Europe every year, with opioids, such as heroin, found in most overdose cases. Yet with adequate intervention, using the overdose-reversal drug naloxone, many of these deaths can be prevented. This issue is explored today in a new report from the EU drugs agency (EMCDDA) entitled Preventing opioid overdose deaths with take-home naloxone. Read more > >

Registration opens for fifth European drugs summer school

(Lisbon, 07.01.2016) The University Institute of Lisbon (ISCTE-IUL) and the EU drugs agency (EMCDDA) will be joining forces this summer to hold the fifth European drugs summer school (EDSS) on ‘Illicit drugs in Europe: demand, supply and public policies’. Registration opens today for the two-week course, which will take place in the Portuguese capital from 27 June to 8 July. The initiative is also supported by the US National Institute on Drug Abuse (NIDA). Read more > >

Alexis Goosdeel at helm of EU drugs agency

(Lisbon, 04.01.2016) Alexis Goosdeel (Belgium) took up the post of EMCDDA Director on 1 January 2016, having been formally appointed to the position by the agency’s Management Board in October 2015 for a five-year term. Read more > >

EMCDDA Management Board elects new Chair and Vice-Chair

(Lisbon, 03.12.2015) The EU drugs agency Management Board kicked off a two-day meeting in Lisbon today, holding elections for Chair and Vice-Chair of the Board. Read more > >

New EMCDDA report explores combined mental health and substance use disorders

(Lisbon, 27.11.2015) The co-existence of mental illness and psychoactive drug or other substance use problems — otherwise known as ‘comorbidity’ or ‘dual diagnosis’ — is an issue which has been on the radar of the EU drugs agency (EMCDDA) for over a decade. As concern around the issue grows, the EMCDDA publishes today the most comprehensive analysis of the topic to date at European level: Comorbidity of substance use and mental disorders in Europe. Read more > >

Over 40 countries attend 2015 Reitox week in Lisbon

(Lisbon, 23.11.2015) Representatives of candidate, potential candidate and neighbouring countries of the EU are joining members of the EMCDDA’s Reitox network in Lisbon today for the kick-off of the agency’s fourth Reitox week. The purpose of this annual event is to broaden the scope of regular Reitox meetings, underline the importance of the EU drug monitoring model and add impetus to the agency’s technical cooperation with countries outside the EU. Read more > >

EU drugs agency boosts cooperation with Georgian Ministry of Justice

(Lisbon, 04.11.2015) EMCDDA Director Wolfgang Götz and the Georgian Minister of Justice Tea Tsulukiani are meeting in Tbilisi today to sign a Memorandum of Understanding (MoU). The agreement, between the agency and the Georgian Ministry of Justice, will boost cooperation between the two bodies in monitoring the drugs problem and facilitate the collection, processing and dissemination of information. Read more > >

4,4'-DMAR and MT-45 to be placed under control across the EU

(Lisbon, 20.10.2015) Europe has responded to rising concerns over the use of two new drugs by subjecting them to ‘control measures and criminal penalties’ throughout the Union. The implementing decision of the Council of the EU, published in the Official Journal of the European Union today, was adopted in the final stage of the three-step legal procedure designed to respond to potentially threatening new psychoactive substances (NPS) available on the market. Read more > >

EMCDDA co-hosts ‘Testing the waters 2015’

(Lisbon, 09.10.2015) The EU drugs agency (EMCDDA) is co-hosting next week in Ascona, Switzerland, the second international conference on wastewater analysis: ‘Testing the waters 2015’. The event, to be held from 11–15 October, is organised by the Swiss Federal Institute of Aquatic Science and Technology (Eawag), in association with the EU-funded SEWPROF project and the Europe-wide sewage analysis CORE group, SCORE. It also counts on generous support from the Centro Stefano Franscini (CSF/ETHZ).  Read more >>

Annual award ceremony to celebrate excellence in scientific writing on illicit drugs

(Lisbon, 22.09.2015)  The winners of the 2015 EMCDDA scientific paper award will gather in Lisbon on 23 September for the fifth annual paper award ceremony hosted by the EU agency. The acclaimed writers will receive a non-monetary prize for their articles in the margins of the Lisbon Addictions 2015 conference opening this week in the Portuguese capital. Read more >>

EMCDDA conference: 20 years of monitoring and communicating evidence on drugs

(Lisbon, 18.09.2015)  Understanding the dynamics, nature and scale of drug use in Europe, including lessons learnt and challenges for the future, will be the thrust of an EMCDDA technical conference being held in Lisbon from 21–22 September. The event, organised ahead of Lisbon Addictions 2015, commemorates the EU agency’s 20 years of monitoring and communicating evidence on drugs. Read more >>

EMCDDA Management Board selects new Director

(Lisbon, 10.09.2015)  EMCDDA Alexis Goosdeel (Belgium) was selected today by the Management Board to become the new Director of the EMCDDA. He will succeed Wolfgang Götz (Germany), who has headed the agency since 1 May 2005 and who will remain Director until the end of the year. Read more >>

EMCDDA Director Wolfgang Götz receives award for services to the Republic of Austria

(Lisbon, 08.09.2015)  EMCDDA Wolfgang Götz will be guest of honour at the Austrian Embassy in Lisbon this evening where he will be awarded the Grand Decoration of Honour in Gold for Services to the Republic of Austria. The award will be bestowed on Mr Götz by His Excellency the Ambassador of Austria Thomas Stelzer.  Read more >>

EMCDDA celebrates 20 years of monitoring

(Lisbon, 02.09.2015)  This year, the EMCDDA commemorates 20 years of monitoring the drugs problem in Europe. Over the last two decades, much has changed in the extent and nature of the phenomenon. EMCDDA Director Wolfgang Götz reflects.  Read more >>

EU drugs agency steps up cooperation with National Security Council of Armenia

(Lisbon, 16.07.2015) The European Union and Armenia will cooperate more actively on monitoring the drug phenomenon in future, thanks to a Memorandum of Understanding (MoU) signed today in Yerevan between the EU drugs agency (EMCDDA) and the National Security Council of Armenia (NSC). The agreement was signed by EMCDDA Director Wolfgang Götz and NSC Chief of staff, Aram Tananyan. Read more >>

Europe’s cities offer valuable observation window on new drug trends

(Lisbon, 25.06.2015) Drug problems often emerge, and are most acutely felt, in urban environments, making Europe’s cities a valuable observation window on new drug trends. In its latest report — released today ahead of International day against drug abuse and illicit trafficking (26 June) — the EU drugs agency (EMCDDA) looks at drugs in cities across Europe, revealing how some cities are developing drug strategies of their own. Read more >>

Director presents highlights from the European Drug Report 2015: Trends and Developments, at European Parliament

(Brussels,17.06.2015) EMCDDA Director Wolfgang Götz is at the European Parliament today presenting to members of the Committee for Civil Liberties, Justice and Home Affairs (LIBE) highlights from the European Drug Report 2015: Trends and Developments. Read transcripts of the speeches >>

European Drug Report 2015: EMCDDA explores new dynamics and dimensions of Europe’s drugs problem

(Lisbon, 04.06.2015) Changing dynamics in the heroin market, the latest implications of cannabis use and new features and dimensions of the stimulant and ‘new drugs’ scene, are among the issues highlighted by the EU drugs agency (EMCDDA) today as it launches its European Drug Report 2015: Trends and Developments in Lisbon. In its annual review, the agency reflects on 20 years of monitoring and examines the global influences and local ramifications of Europe’s ever-changing drugs problem. Read more >>

Delegation of Irish Parliament to visit EMCDDA

(Lisbon, 03.06.2015) A delegation of members of the Joint Committee on Justice, Defence and Equality of the Irish Parliament will visit the EMCDDA on 4 and 5 June. The Attaché of the Embassy of of Ireland in Portugal, Ms Ana von Holst, will accompany the delegation. The members of the Irish Parliament will attend the launch of the European Drug Report 2015 on 4 June. Read more >>

Coming soon: European Drug Report 2015

(Lisbon, 15.04.2015) What are the latest drug market trends and what are the factors driving them? What are the most recent developments in drug prevention, treatment and policy? How many new drugs were detected in Europe over the last year and what are the consequences for those using them? These and other questions will be explored by the EU drugs agency (EMCDDA) on 4 June in its annual overview of the European drug situation. Read more >>

EMCDDA underlines growing importance of effective treatment for cannabis use

(Lisbon, 21.04.2015) Providing effective treatment for those with cannabis use disorders is likely to become a matter of growing importance in European drug policy. This is according to the EU drugs agency (EMCDDA) today as it launches a new in-depth study: Treatment of cannabis-related disorders in Europe. Read more >>

EMCDDA publishes first overview of the drug situation in the Western Balkans

(Lisbon, 23.03.2015) The EU drugs agency (EMCDDA) publishes today its first overview of the drug situation in the Western Balkans. Focusing on Albania, Bosnia and Herzegovina, the former Yugoslav Republic of Macedonia, Kosovo, Montenegro and Serbia — all candidate and potential candidate countries to the European Union — the report describes a region facing a complex array of drug use problems and associated health and social consequences. It focuses specifically on problem drug use, drug-related deaths, the health effects of injecting and treatment and harm reduction responses. Read more >>

EMCDDA participates in SEEA-net events

(Lisbon/Vienna, 12.03.2015) The EMCDDA is participating this week in the 7th Conference of the South Eastern European Adriatic (SEEA) Addiction Treatment Network and the 14th SEEA-net Symposium on Addictive Behaviours. Alexis Goosdeel, EMCDDA Head of unit for Reitox and international cooperation will be examining the challenges of new psychoactive substances and will be presenting the findings of a report on Drug use and its consequences in the Western Balkans (2006-14), due for release this month. Read more >>

EMCDDA presents latest update on ‘new drugs’ from EU Early Warning System

(Lisbon/Vienna, 09.03.2015) New psychoactive substances (NPS or ‘new drugs’) were detected in the European Union last year at the rate of around two per week, according to an update issued today by the EU drugs agency (EMCDDA). A total of 101 new substances were reported to the EU Early Warning System (EWS) in 2014 (up from 81 in 2013), continuing an upward trend in substances notified in a single year.  Read more >>

58th Commission on Narcotic Drugs, 9–17 March, Vienna

(Lisbon/Vienna, 09.03.2015) The United Nations Commission on Narcotic Drugs (CND), the central UN policy-making body in drug-related matters, opens its 58th session in Vienna this week (9–17 March). The CND analyses the world drug situation and develops proposals to strengthen the international drug control system. An EMCDDA delegation is attending the event and, throughout the week, will provide technical support to the European Commission and EU Member States. Visitors are welcome to the EMCDDA stand.  Read more >>

EMCDDA hosts Euro-DEN meeting and promotes new guidelines

(Stockholm/Lisbon, 16.02.2015) The recreational drug scene has evolved rapidly over the last decade, with new psychoactive substances (NPS) posing additional challenges. To address deficiencies in the data available, the European Drug Emergencies Network (Euro-DEN) project was established in 2013, funded through the European Commission’s Drug Prevention and Information Programme. The EMCDDA is a member of the Euro-DEN Steering Committee and is hosting its latest meeting in Lisbon today. Read more >>

ECDC and EMCDDA release a joint rapid risk assessment on wound botulism among people who inject heroin

(Stockholm/Lisbon, 16.02.2015) Today, two EU agencies, the European Centre for Disease Prevention and Control (ECDC) and the EU drugs agency (EMCDDA) have released a joint rapid risk assessment on wound botulism among people who inject heroin. This joint risk assessment follows a request by the European Commission’s Directorate-General for Health and Food Safety, in response to an increase in the number of cases of wound botulism in this group reported in two EU Member States. Read more >>

EMCDDA welcomes new moves to make hepatitis C medications more accessible to patients

(Lisbon, 12.02.2015) The EU drugs agency (EMCDDA) welcomes new moves to make hepatitis C medications more accessible to those affected by the virus. Hepatitis C is the most common infectious disease in injecting drug users, among whom it is usually transmitted through the sharing of injecting equipment such as needles and syringes. Read more >>

New EMCDDA annual work programme published today

(Lisbon, 12.02.2015) The EMCDDA has published today its 2015 annual work programme, adopted by its Management Board on 5 December. The new programme sets out the objectives for the final year of the agency’s 2013–15 strategy and promises to build a solid bridge between current priorities and those defined for the next three years (2016–18). Read more >>

Customs Laboratories European Network (CLEN) meeting

(Lisbon, 06.02.2015) The Portuguese Taxes and Customs Authority and the EMCDDA are hosting in Lisbon this week the second meeting of the European Commission’s (EC) Customs Laboratories European Network (CLEN) project group, funded by the EC Customs 2020 programme. The meeting is focusing on ‘Designer drugs and other illicit products’ Read more >>

Mortality among drug users in Europe

(Lisbon, 03.02.2015) Drug use is one of the major causes of mortality among young people in Europe, both directly through overdose and indirectly through drug-related diseases, accidents, violence and suicide. To gain a clearer picture of the overall number of lives lost due to drug use in Europe, a new EMCDDA Paper investigates ‘all-cause’ mortality among problem drug users. Read more >>

New EMCDDA trendspotter study explores online supply of drugs

(Lisbon, 30.01.2015) The speed with which the Internet is transforming drug markets poses a major challenge to law enforcement, public health, research and monitoring agencies. This is according to The Internet and drug markets, the latest ‘trendspotter’ study from the EU drugs agency (EMCDDA) released today. The study aims to raise understanding of the current online supply of drugs and to map the range of Internet markets in existence. Read more >>

Drug policies in the perspective of UNGASS 2016

(Brussels, 27.01.2015) EMCDDA Director Wolfgang Götz is at the European Parliament today for an exchange of views with European members of the Global Commission on Drug Policy ahead of the United Nations General Assembly Special Session on drugs (UNGASS 2016). Read transcript of the speech >>

Director presents highlights from EMCDDA 2015 work programme at European Parliament

(Brussels, 21.01.2015) EMCDDA Director Wolfgang Götz is at the European Parliament today where he is presenting to members of the Committee for Civil Liberties, Justice and Home Affairs (LIBE) highlights from the agency’s 2015 work programme and developments in the monitoring of new psychoactive substances. Read transcripts of the speeches >>

New EMCDDA review studies the effectiveness of overdose antidote, naloxone

(Lisbon, 19.01.2015) Can naloxone provided in the community help reduce the thousands of drug-induced deaths recorded in Europe every year? This is the question explored by the EU drugs agency (EMCDDA) in a new paper released today: Preventing fatal overdoses: a systematic review of the effectiveness of take-home naloxone. Read more >>

Registration opens for fourth European drugs summer school

(Lisbon, 15.01.2015) The University Institute of Lisbon (ISCTE-IUL) and the EU drugs agency (EMCDDA) will be joining forces again this summer to hold the fourth European drugs summer school (EDSS) on 'Illicit drugs in Europe: demand, supply and public policies'. Registration opens today for the two-week course, which will take place in the Portuguese capital from 29 June to 10 July. The initiative is also supported by the US National Institute on Drug Abuse (NIDA). Read more >>

Gaps in HIV prevention expose Europe to risk of outbreaks

(Lisbon, 01.12.2014) In Europe, decades of investment in effective HIV prevention measures targeting people who inject drugs continue to bear fruit as demonstrated by the long-term decline HIV diagnoses related to drug injecting. Over the past ten years, the rate of newly reported HIV diagnoses attributed to injecting drug use in the EU, Turkey and Norway has more than halved from 52 per million population in 2004 (2644 cases) to 25 in 2013 (1458 cases). Read more >>

Annual award ceremony to celebrate excellence in scientific writing on illicit drugs

(Lisbon, 24.11.2014) The four winners of the 2014 EMCDDA scientific paper award will be honoured in Lisbon on 25 November at the fourth annual award ceremony hosted by the EU agency. The winners will receive a non-monetary prize for their contributions in the margins of the third ‘Reitox week’ initiative, which gathers representatives from around 40 national drug monitoring centres. Read more >>

EMCDDA to host third Reitox week

(Lisbon, 19.11.2014) Real-life responses to drug problems come under the spotlight today as the EU drugs agency (EMCDDA) launches its revamped Best practice portal. Designed as a practical and reliable source of what works, and what doesn’t, in the areas of drug-related prevention, treatment, harm reduction and social reintegration, the portal is targeted at practitioners and professionals. Read more >>

Pregnancy and opioid use: strategies for treatment

(Lisbon, 23.10.2014) Illicit opioid consumption is associated with an increase in obstetric complications in pregnant women. It also brings with it a range of potential dangers for the child, both before and after birth. Neonatal complications include narcotic withdrawal, postnatal growth deficiency, microcephaly, neurobehavioural problems, increase in neonatal mortality and an increase in sudden infant death syndrome. Read more >>

Click and learn with the EMCDDA’s new-look Best practice portal

(Lisbon, 23.10.2014) Real-life responses to drug problems come under the spotlight today as the EU drugs agency (EMCDDA) launches its revamped Best practice portal. Designed as a practical and reliable source of what works, and what doesn’t, in the areas of drug-related prevention, treatment, harm reduction and social reintegration, the portal is targeted at practitioners and professionals. Read more >>

Drug-related harms and responses in focus at annual EMCDDA expert meetings

(Lisbon, 13.10.2014) Latest evidence in the area of drug overdose, HCV infections and HIV outbreaks among drug users will be among the topics discussed in a series of events unfolding this week at the EU drugs agency (EMCDDA) in Lisbon Read more >>

Second EMDAS graduation ceremony at EMCDDA

(Lisbon, 29.09.2014) The second group of 25 students graduating from the European Masters in Drug and Alcohol Studies (EMDAS), will receive their diplomas at a ceremony at the EMCDDA on 30 September. EMDAS, a project initially funded through the EC-Lifelong Learning Programme, involves three European universities: Århus (Denmark); Universidad Miguel Hernández de Elche (Spain); and Piemonte Orientale ‘A. Avogardo’ (Italy). Read more >>

Four new drugs to be placed under control

(Lisbon, 25.09.2014) Today, EU Ministers adopted a European Commission proposal to control four new psychoactive substances currently raising health concerns in Europe. Read more >>

EMCDDA unites expert networks in integrated approach to monitoring

(Lisbon, 24.09.2014) ‘Continuity and change: high-risk drug use and drug treatment in Europe’, is the focus of events unfolding this week at the EU drugs agency (EMCDDA) in Lisbon. Two parallel EMCDDA expert meetings, dedicated to the agency’s treatment demand indicator (TDI) and the problem drug use indicator (PDU), precede a broader, common event open to specialists from outside the two groups. Read more in fact sheet 10/2014>>

European Parliament President Martin Schulz to visit EU agencies in Lisbon

(Lisbon, 19.09.2014) Newly re-elected President of the European Parliament Martin Schulz will visit the EU drugs agency (EMCDDA) and the European Maritime Safety Agency (EMSA) on 23 September, accompanied by Secretary of State for European Affairs Bruno Maçães and Mayor of Lisbon António Costa. Read more in news release 8/2014>>

European scientists to assess risks of new stimulant drug 4,4′-DMAR

(Lisbon, 16.09.2014) Leading European scientists convene in Lisbon today to undertake the risk assessment of a new psychoactive substance currently raising health concerns in Europe. The substance in question, the stimulant drug 4,4′-DMAR, is the fifth new drug to be risk assessed this year. Read more >>

ECDC-EMCDDA joint mission on HIV status and hepatitis surveillance in Latvia

(Lisbon, 03.09.2014) At the invitation of the Latvian government, and in the context of high HIV levels in the country, ECDC and the EMCDDA have joined forces to assist national experts in preventing and controlling infectious diseases among different risk groups, including people who inject drugs. Read more >>

Published today: New EMCDDA review on hepatitis C virus infection among people who inject drugs in Europe

(Lisbon, 28.07.2014) People who inject drugs (PWID) are a key population affected by the hepatitis C virus (HCV). Treatment options are improving and may enhance prevention; however access for PWID may be poor. To coincide with World Hepatitis Day, the open-access online journal PLOS ONE publishes the results of an EMCDDA systematic review on data for the scaling up of HCV treatment and prevention for PWID across the European Union. Read more >>

Over 30 years’ experience in the cross-border collection and analysis of information

(Lisbon, 15.07.2014) Wolfgang Götz has been Director of the EMCDDA since May 2005, having been appointed by the agency’s Management Board on 19 April that year. In July 2009, the Board renewed his mandate unanimously for a further five-year term commencing on 1 May 2010. See updated profile here. Read more in fact sheet 8/2014 >>

Eurojust and EMCDDA pledge to boost cooperation

(Lisbon, 15.07.2014) Exchanging strategic and technical information in the areas of drug legislation and supply was among the pledges made today in a Memorandum of Understanding (MoU) signed by the EU drugs agency (EMCDDA) and the EU judicial cooperation unit (Eurojust). At an official ceremony in The Hague, EMCDDA Director Wolfgang Götz and President of Eurojust Michèle Coninsx reaffirmed their agencies’ commitment to strengthening action against illicit drugs and related crime in the EU. Read more in news release 7/2014 >>

Third European drugs summer school opens today in Lisbon

(Lisbon, 30.06.2014) The third European drugs summer school (EDSS) — ‘Illicit drugs in Europe: demand, supply and public policies’ — opens today in Lisbon and will run until 11 July. The initiative, organised by the University Institute of Lisbon (ISCTE) and the EU drugs agency (EMCDDA), is supported by the US National Institute on Drug Abuse (NIDA). Read more in fact sheet 7/2014 >>

EMCDDA releases state-of-the-art review on drugs and driving

(Lisbon, 25.06.2014) An estimated 28 000 lives are lost on Europe’s roads every year and a further 1.34 million people are injured. Many of these accidents and deaths are caused by drivers whose performance is impaired by a psychoactive substance.  In a new report out today, Drug use, impaired driving and traffic accidents, the EU drugs agency (EMCDDA) reviews the latest research in this field. Read more in news release 6/2014 >>

Largest multi-city study on drug wastewater analysis released today

(Lisbon, 27.05.2014) The findings of the largest European project to date in the emerging science of wastewater analysis (WWA) are released today in an article published in Addiction. The project in question — steered by the Europe-wide SCORE network — analysed wastewater in over 40 European cities to explore the drug-taking habits of those who live in them. Read more in news release 5/2014 >>

EU drugs agency places six topics in the spotlight with new online analyses

(Lisbon, 27.05.2014) The EMCDDA releases today alongside its European Drug Report 2014: Trends and developments, six new additions to its Perspectives on drugs (PODs) series. This latest selection of online, interactive analyses provides a state-of-the-art review of key aspects of the European drug situation. Read more in news release 4/2014 >>

European Drug Report out today — Europe’s drugs problem ‘increasingly complex’

(Lisbon, 27.05.2014) Europe’s drugs problem is becoming increasingly complex with new challenges emerging that raise concerns for public health. This is according to the European Drug Report 2014: Trends and developments released today by the EMCDDA. Read more in news release 3/2014 >>

International experts to examine latest findings in the field of new drugs

(Lisbon, 15.05.2014) Third international conference on novel psychoactive substances opens today in Rome. Read more in fact sheet 6/2014 >>

EU drugs agency to launch European Drug Report 2014

(Lisbon, 24.04.2014) The EMCDDA will be presenting its annual overview of the European drug situation on 27 May in a multilingual, multimedia information package focusing on today’s rapidly shifting drug phenomenon. Read more in news release 2/2014 >>

EMCDDA and ECDC facilitate sub-regional exchange of knowledge and best practice in monitoring and preventing drug-related infections

(Lisbon, 07.04.2014) Monitoring and responding to HIV and hepatitis C among people who inject drugs (PWID) is the focus of two new reports from the EU drugs agency (EMCDDA) and the European Centre for Disease Prevention and Control (ECDC). Read more >>

EMCDDA Scientific Committee elects new leaders

(Lisbon, 01.04.2014) The EMCDDA Scientific Committee, meeting in Lisbon this week, elected its new Chair and Vice Chair for the next three years. Prof. Dr Gerhard Bühringer (Germany) was elected to the position of Chair and Dr Anne Line Breteville-Jensen (Norway) to the position of Vice Chair. Read more in fact sheet 5/2014 >>

Regional drug strategies across the world explored in new EMCDDA paper

(Lisbon, 18.03.2014) The EU drugs agency (EMCDDA) has released today its first comparative analysis of regional drug strategies across the world. The paper explores the drug strategies and action plans adopted over the last five years by six intergovernmental organisations, engaging 148 countries in four continents. Read more in fact sheet 4/2014 >>

Dangerous synthetic drugs hit the EU market

(Lisbon, 07.03.2014) Europol and the EMCDDA have issued today early-warning notifications about two synthetic drugs that have recently been linked to serious harms in the EU. Read more >>

New EMCDDA technical assistance project with ENP countries kicks off today

(Lisbon, 05.03.2014) A new, two-year technical cooperation project between the EU drugs agency (EMCDDA) and countries of the European Neighbourhood Policy (ENP) kicks off today in Lisbon. The project takes place within the EMCDDA’s mandate for cooperation with third (non-EU) countries, as set out in its recast founding regulation in 2006. Read more in fact sheet 3/2014 >>

EMCDDA embarks on 2014 work programme

(Lisbon, 13.02.2014) The EMCDDA’s 2014 work programme — adopted by the Management Board on 5 December and published today — takes forward work begun in 2013 to implement the core principles of the EMCDDA’s 2013–15 strategy and work programme. Three core principles drive this three-year strategy and also shape and focus activities in 2014. These include: delivering a relevant, timely and responsive analysis of the drug situation; achieving efficiency and ensuring that maximum value is delivered from activities and investments; and enhancing communication and a customer-focused approach. Read more >>

EU drugs agency steps up cooperation with Israel Anti-Drug Authority

(Lisbon, 04.02.2014) The European Union and Israel will share information on drugs more systematically in future, thanks to a Memorandum of Understanding signed today in Jerusalem between the EMCDDA and the Israel Anti-Drug Authority (IADA). The agreement was signed at the Israeli Ministry of Foreign Affairs by EMCDDA Director Wolfgang Götz and IADA Director-General Yair Geller. Read more in fact sheet 2/2014 >>

EMCDDA hosts kick-off meeting of EC-funded Joint Action on Reducing Alcohol Related Harm

(Lisbon, 31.01.2014) Harmful and hazardous alcohol use is one of the main causes of premature deaths and avoidable diseases in the EU today. Highlighting the importance of this issue, the European Commission is funding the Joint Action on Reducing Alcohol Related Harm (RARHA) project, being launched in Lisbon on 31 January. Read more  >>

Four new drugs go under the microscope in the wake of rising health concerns

(Lisbon, 29.01.2014) Europe has responded to rising concern over the use of four new drugs by formally requesting a scientific investigation into the health and social risks of the substances. The drugs are: 25I-NBOMe, AH-7921, MDPV and methoxetamine. Read more in news release 1/2014 >>

Registration opens for third European drugs summer school

(Lisbon, 15.01.2014) The University Institute of Lisbon (ISCTE–IUL) and the EU drugs agency (EMCDDA) will be joining forces again in July 2014 to hold the third European summer school on ‘Illicit drugs in Europe: supply, demand and public policies’. Registration opens today for the two-week course, which will take place in the Portuguese capital from 30 June to 11 July. The initiative is supported by the US National Institute on Drug Abuse (NIDA). Read more in fact sheet 1/2014 >>


09/11/2015 01:58 PM
About

EMCDDA, your reference point on drugs in Europe

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was established in 1993. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. The EMCDDA exists to provide the EU and its Member States with a factual overview of European drug problems and a solid evidence base to support the drugs debate. Today it offers policymakers the data they need for drawing up informed drug laws and strategies. It also helps professionals and practitioners working in the field pinpoint best practice and new areas of research.


09/11/2015 01:44 PM
Om EMCDDA

EMCDDA, din referens i narkotikafrågor i Europa

Europeiska centrumet för kontroll av narkotika och narkotikamissbruk (EMCDDA) inrättades 1993. EMCDDA invigdes i Lissabon 1995 och är en av EU:s första decentraliserade byråer. EMCDDA:s syfte är att ge EU och dess medlemsstater en objektiv överblick över EU:s narkotikaproblem och en faktabaserad grund för narkotikadebatten. I dag ger centret de politiska beslutsfattarna de uppgifter som behövs för att utarbeta väl underbyggda lagar och strategier gällande narkotika. Den hjälper också yrkesverksamma inom området att fastställa bästa praxis och utveckla nya forskningsområden.


09/11/2015 01:42 PM
Despre EMCDDA

EMCDDA, punctul tău de referinţă pentru situaţia drogurilor în Europa

Observatorul European pentru Droguri şi Toxicomanie (EMCDDA) a fost înfiinţat în anul 1993. Acesta a fost inaugurat în 1995 la Lisabona şi este una dintre agenţiile descentralizate ale Uniunii Europene. EMCDDA are rolul de a oferi UE şi statelor sale membre o imagine reală asupra problemelor legate de droguri în Europa şi o bază solidă de dovezi care să ofere sprijin în cadrul dezbaterilor privind drogurile. În prezent, Observatorul oferă factorilor de decizie datele de care au nevoie pentru elaborarea strategiilor şi legilor privind drogurile. Această agenţie îi ajută, de asemenea, pe profesioniştii şi practicienii care lucrează în domeniu să identifice cele mai bune practici şi noi domenii de cercetare.


09/11/2015 01:42 PM
Sobre o EMCDDA

EMCDDA, a sua referência para a informação sobre droga na Europa

O Observatório Europeu da Droga e da Toxicodependência (EMCDDA) foi criado em 1993. Inaugurado em Lisboa em 1995, é uma das agências descentralizadas da União Europeia. O EMCDDA existe para fornecer à UE e aos seus Estados-membros uma imagem objectiva dos problemas europeus relacionados com droga e uma base científica sólida para sustentar o debate sobre esta matéria. Actualmente, oferece aos decisores políticos os dados de que estes necessitam para formularem leis e estratégias esclarecidas. Ajuda igualmente os profissionais e técnicos que trabalham nesta área a identificarem com precisão as boas práticas e os novos domínios de investigação.


09/11/2015 01:40 PM
Om EMCDDA

EMCDDA, ditt referansepunkt for narkotikaspørsmål i Europa

Europeisk overvåkingssenter for narkotika og narkotikamisbruk (EMCDDA) ble opprettet i 1993. Senteret åpnet i Lisboa i 1995 som ett av EUs desentraliserte byråer. EMCDDA skal gi EU og medlemsstatene en faktabasert oversikt over narkotikasituasjonen i Europa så vel som et solid kunnskapsgrunnlag for narkotikadebatten. Senteret gir i dag beslutningstakere de data som trenges for å utforme narkotikalovgivning og narkotikastrategier på et informert grunnlag. Det hjelper også fagfolk og praktikere på feltet med å søke etter beste praksis og nye områder for forskning.


09/11/2015 01:39 PM
Over het EMCDDA

EMCDDA, een referentiepunt op het gebied van drugs in Europa

Het Europees Waarnemingscentrum voor drugs en drugsverslaving (EMCDDA) werd opgericht in 1993. Het EMCDDA is in 1995 officieel geopend als één van de gedecentraliseerde agentschappen van de EU en is gevestigd in Lissabon. Het doel van het EMCDDA is om de EU en haar lidstaten te voorzien van feitelijke overzichten van de Europese drugsproblematiek en goed onderbouwde bewijsgronden voor het voeren van het drugsdebat. Het verschaft beleidsmakers de benodigde gegevens zodat dezen op geïnformeerde wijze drugswetgeving en -strategieën kunnen opstellen. Ook helpt het EMCDDA behandelaars en andere vakmensen bij het vaststellen van de beste werkwijzen en het identifi ceren van nieuwe onderzoeksgebieden.


09/11/2015 01:37 PM
Informazioni sull’EMCDDA

L’EMCDDA, il punto di riferimento sulle droghe in Europa

L’Osservatorio europeo delle droghe e delle tossicodipendenze (EMCDDA) è stato istituito nel 1993. Inaugurato a Lisbona nel 1995, è una delle agenzie decentrate dell’Unione europea (UE). L’obiettivo dell’EMCDDA consiste nel fornire all’UE e agli Stati membri una visione realistica dei problemi legati alla droga in Europa e una base solida di evidenze che supportino il dibattito sugli stupefacenti. L’EMCDDA offre ai responsabili politici i dati necessari per elaborare leggi e strategie in materia di droga e a professionisti e operatori del settore uno strumento per individuare le «best practice» e nuove aree di ricerca.


09/11/2015 01:36 PM
À propos de l'EMCDDA

L’EMCDDA, votre point de référence en matière de drogue en Europe

L’Observatoire européen des drogues et des toxicomanies (EMCDDA) a été fondé en 1993. Inauguré à Lisbonne en 1995, l’EMCDDA est l’une des agences décentralisées de l’Union européenne (UE). L’EMCDDA a pour vocation de fournir à l’UE et aux États membres une vue d’ensemble factuelle du phénomène de la drogue en Europe et une base d’informations probantes propres à alimenter le débat sur ce sujet. L’Observatoire apporte aujourd’hui aux décideurs politiques les données dont ils ont besoin pour élaborer des lois et stratégies éclairées, et il aide les professionnels et acteurs de terrain à cibler les meilleures pratiques et les nouveaux domaines de recherche.


09/11/2015 01:35 PM
Acerca del EMCDDA

EMCDDA, su punto de referencia en materia de drogas en Europa

En 1993 se creó el Observatorio Europeo de las Drogas y las Toxicomanías (EMCDDA). Inaugurado en Lisboa en 1995, el Observatorio es una de las agencias descentralizadas de la Unión Europea (UE). La misión del EMCDDA es proporcionar a la UE y a sus Estados miembros una visión objetiva del problema de las drogas en Europa y una base sólida sobre la que fundamentar el debate en esta materia. En la actualidad, el EMCDDA ofrece a los responsables políticos la información que necesitan para preparar leyes y estrategias bien fundamentadas en materia de drogas. La agencia también ayuda a los profesionales e investigadores de este campo a identifi car buenas prácticas y nuevas áreas de investigación.


09/11/2015 01:34 PM
Σχετικά με το EMCDDA

EMCDDA, το δικό σας σημείο αναφοράς για τα ναρκωτικά στην Ευρώπη

Το Ευρωπαϊκό Κέντρο Παρακολούθησης Ναρκωτικών και Τοξικομανίας (EMCDDA) ιδρύθηκε το 1993. Το Κέντρο εγκαινιάστηκε το 1995 στη Λισαβόνα και αποτελεί έναν από τους αποκεντρωμένους οργανισμούς της ΕΕ. Ο ρόλος του EMCDDA είναι να παρέχει στην ΕΕ και στα κράτη μέλη της μια αντικειμενική συνολική εικόνα του προβλήματος των ναρκωτικών στην ΕΕ και μια αξιόπιστη τεκμηρίωση προς υποστήριξη της συζήτησης επί του θέματος αυτού. Σήμερα, παρέχει στους αρμόδιους χάραξης πολιτικής τεκμηριωμένα δεδομένα για τη σύνταξη νομοθεσίας και την κατάρτιση στρατηγικών για τα ναρκωτικά, ενώ επίσης βοηθά τους επαγγελματίες και τους ερευνητές που εργάζονται στον συγκεκριμένο τομέα να στοχεύουν σε βέλτιστες πρακτικές και νέους τομείς έρευνας.


09/11/2015 01:33 PM
Über das EMCDDA

Das EMCDDA, Ihre Referenzstelle zu Drogenfragen in Europa

Die Europäische Beobachtungsstelle für Drogen und Drogensucht (EMCDDA) wurde im Jahr 1993 errichtet. Sie gehört zu den dezentralen Agenturen der EU und nahm 1995 in Lissabon ihre Tätigkeit auf. Das EMCDDA soll der EU und ihren Mitgliedstaaten einen sachlichen Überblick über die europäische Drogenproblematik vermitteln und solide faktengesicherte Grundlagen zur Drogendebatte liefern. Es versorgt politische Entscheidungsträger mit dem Datenmaterial, das diese zur Ausarbeitung fundierter Rechtsvorschriften und Strategien im Drogenbereich benötigen, und unterstützt Fachleute und Praktiker dabei, Projekte mit Modellcharakter und neue Forschungsgebiete aufzuzeigen.


09/11/2015 01:31 PM
За EMCDDA

EMCDDA - вашият компетентен източник по проблемите на наркотиците в Европа

През 1993 г. беше създаден Европейският център за мониторинг на наркотиците и наркоманиите (EMCDDA). Официално открит в Лисабон през 1995 г., центърът е една от децентрализираните агенции на ЕС. EMCDDA е създаден, за да предоставя на ЕС и държавите-членки реалната картина на проблемите с наркотиците в Европа, както и надеждни научни данни в помощ на дебата за тях. Днес той предлага на тези, които разработват политиките, данните, необходими за изготвяне на научно обосновани закони и стратегии в областта на наркотиците. Наред с това центърът помага на специалистите и практикуващите лекари, работещи в тази сфера, да определят точно най-добрите практики и новите области за анализ

 


09/09/2015 03:55 PM
O agentúre EMCDDA

EMCDDA, vaše referenčné miesto o drogách v Európe

Európske monitorovacie centrum pre drogy a drogovú závislosť (EMCDDA) bolo zriadené v roku 1993. Centrum bolo slávnostne otvorené v roku 1995 v Lisabone a je jednou z decentralizovaných agentúr EÚ. Úlohou EMCDDA je poskytovať EÚ a jej členským štátom faktický prehľad o európskej drogovej problematike a spoľahlivé dôkazy na podporu diskusie o drogách. Politickým činiteľom v súčasnosti ponúka údaje, ktoré sú potrebné na vypracovanie kvalifikovaných právnych predpisov a stratégií týkajúcich sa drog. Centrum takisto pomáha odborníkom a ľuďom z praxe, ktorí pracujú v tejto oblasti, identifikovať osvedčené postupy a nové oblasti výskumu.


09/09/2015 03:35 PM
Informacje o EMCDDA

EMCDDA, twój punkt informacji o narkotykach w Europie

Europejskie Centrum Monitorowania Narkotyków i Narkomanii (EMCDDA) utworzono w 1993 r. Działalność EMCDDA, będącego jedną ze zdecentralizowanych agencji UE, zainaugurowano w Lizbonie w 1995 r. Celem istnienia EMCDDA jest zapewnianie UE i jej państwom członkowskim wiarygodnego obrazu zjawiska narkotyków i narkomanii w Europie oraz dostarczenie rzetelnych informacji naukowych wspierających dyskusję poświęconą narkotykom. Obecnie Centrum dostarcza decydentom dane potrzebne do przygotowywania odpowiednich rozwiązań legislacyjnych oraz strategii narkotykowych. Pomaga także fachowcom i specjalistom w tej dziedzinie na określenie najlepsze praktyk i nowych obszarów badań.


09/09/2015 03:32 PM
Par EMCDDA

EMCDDA — tavs izziņu avots narkotiku jautājumos Eiropā

Eiropas Narkotiku un narkomānijas uzraudzības centrs (EMCDDA) tika dibināta 1993. gadā. To svinīgi atklāja 1995. gadā Lisabonā. Centrs ir viena no ES decentralizētajām aģentūrām. EMCDDA mērķis ir nodrošināt Eiropas Savienībai un tās dalībvalstīm faktu izklāstu par narkotiku problēmām Eiropā un pamatotu pierādījumu bāzi, lai atbalstītu debates par narkotikām. Patlaban centrs piedāvā politikas veidotājiem datus, kas tiem nepieciešami, lai izstrādātu pamatotus tiesību aktus un stratēģijas narkotiku apkarošanas jomā. Centrs arī palīdz šajā jomā strādājošajiem profesionāļiem un speciālistiem noteikt paraugpraksi un jaunus pētījumu virzienus.


09/09/2015 03:28 PM
Apie EMCDDA

EMCDDA, jūsų informacijos apie narkotikus centras Europoje

Europos narkotikų ir narkomanijos stebėsenos centras (EMCDDA) buvo įsteigtas 1993 metais. Nuo 1995 m. Lisabonoje įsikūręs EMCDDA yra viena iš ES decentralizuotų agentūrų. Europos narkotikų ir narkomanijos stebėsenos centras įsteigtas tam, kad ES ir valstybėms narėms teiktų narkotikų keliamų problemų Europoje apžvalgą ir patikimą pagrindą diskusijoms apie narkotikų daromą žalą. Politikos formuotojams centras suteikia duomenų, kurie būtini priimant pagrįstus teisės aktus ir rengiant strategijas. Jis taip pat padeda šioje srityje dirbantiems profesionalams ir specialistams tiksliai nustatyti geriausią praktiką ir naujas mokslinių tyrimų sritis.


09/09/2015 03:23 PM
Az EMCDDA-ról

EMCDDA, a kábítószerügyi tájékoztatási pont Európában

A Kábítószer és Kábítószerfüggőség Európai Megfigyelőközpontját (EMCDDA) 1993-ban alapították meg. Az 1995-ös lisszaboni megnyitó óta a központ az EU decentralizált ügynökségeinek egyike. Az EMCDDA fennállásának célja, hogy az EU és tagállamai számára tárgyilagos áttekintést adjon az európai kábítószer-problémáról, és szilárd bizonyítékokkal támassza alá a kábítószerekről folyó vitát. A központ által biztosított adatok a döntéshozók számára lehetővé teszik, hogy a kábítószerrel összefüggő jogszabályokat és stratégiákat a megfelelő információk birtokában alkossák meg. Emellett a központ segíti a szakértőket és a területen dolgozó gyakorlati szakembereket a legjobb gyakorlatok és az új kutatási területek kijelölésében.


09/09/2015 03:21 PM
O EMCDDA-u

O EMCDDA-u

EMCDDA – vaš izvor informacija o drogama u Europi

Europski centar za praćenje droga i ovisnosti o drogama (EMCDDA) osnovan je 1993. Centar je otvoren 1995. u Lisabonu i jedna je od decentraliziranih agencija EU-a. Zadatak EMCDDA-e je da Europskoj uniji i njezinim članicama pruži pregled činjenica na temu europske problematike droga kao i solidnu bazu dokaza kao podršku u raspravi o drogama. On danas donositeljima politike nudi informacije potrebne pri kreiranju novih zakona i razvijanju odgovarajućih strategija. Centar istovremeno pomaže stručnjacima i djelatnicima u tom području isticanjem najboljih praksi i novih područja istraživanja.


09/09/2015 03:16 PM
Tietoa EMCDDA:sta

EMCDDA, huumausaineiden tietokeskus Euroopassa

Euroopan huumausaineiden ja niiden väärinkäytön seurantakeskus (EMCDDA) perustettiin vuonna 1993 täyttämään tämä tarve, samalla kun huumeilmiö jatkoi voimistumistaan. Lissabonissa vuonna 1995 toimintansa aloittanut keskus on yksi EU:n erillisvirastoista. EMCDDA:n tehtävänä on tarjota EU:lle ja sen jäsenvaltioille tosiasioihin pohjautuvaa tietoa Euroopan huumeongelmista ja vahvaa näyttöä huumeista käytävän keskustelun tueksi. Se tarjoaa päättäjille tietoa, jota he tarvitsevat perusteltujen lakien ja strategioiden laatimiseen huumausaineiden alalla. Lisäksi se auttaa alalla toimivia asiantuntijoita ja ammattilaisia tunnistamaan hyviä toimintatapoja ja uusia tutkimuskohteita.


09/09/2015 03:06 PM
About EMCDDA

EMCDDA, Sinu Euroopa narkoteabe infokeskus

Euroopa Narkootikumide ja Narkomaania Seirekeskus (EMCDDA) asutati 1993. aastal. 1995. aastal Lissabonis tegevust alustanud keskus on üks Euroopa detsentraliseeritud ametitest. EMCDDA eesmärk on anda Euroopa Liidule ja liikmesriikidele faktipõhine ülevaade Euroopa narkoprobleemidest ning toetada narkoteemalisi arutelusid tõenduspõhise teabega. Keskus pakub poliitikakujundajatele narkootikume käsitlevate õigusaktide ja strateegiate koostamiseks vajalikke andmeid. Samuti aitab ta selle valdkonna asjatundatel ja töötajatel lähtuda parimatest praktikatest ning määratleda uusi uurimisteemasid.


09/09/2015 03:00 PM
Om EMCDDA

EMCDDA, dit referencepunkt for oplysninger om narkotikasituationen i Europa

Det Europæiske Overvågningscenter for Narkotika og Narkotikamisbrug (EMCDDA) blev oprettet i 1993. Det blev indviet i Lissabon i 1995 og er et af EU’s decentraliserede agenturer. Formålet med EMCDDA er at levere et faktuelt overblik over om Europas narkotikaproblemer til EU og dens medlemsstater og et solidt evidensgrundlag, der kan understøtte debatten på området. I dag leverer agenturet oplysninger til politikerne til brug ved udformningen af velunderbyggede love og strategier på narkotikaområdet. Det bistår også fagfolk på området med at identifi cere bedste praksis og afdække nye forskningsområder.


09/09/2015 02:59 PM
O EMCDDA

EMCDDA, Váš referenční bod v otázkách drog v Evropě

Evropské monitorovací centrum pro drogy a drogovou závislost (EMCDDA) bylo zřízeno v roce 1993. Centrum EMCDDA, které je jednou z decentralizovaných agentur Evropské unie, zahájilo svou činnost v roce 1995 a sídlí v Lisabonu. Úkolem EMCDDA je poskytovat EU a jejím členským státům faktický přehled o evropských problémech v oblasti drog a spolehlivou znalostní základnu na podporu diskuse o drogách. Politickým činitelům dnes nabízí údaje, které potřebují ke kvalifikované přípravě právních předpisů a formulování strategií týkajících se drog. Centrum rovněž pomáhá odborníkům a pracovníkům z praxe působícím v této oblasti upozorňovat na osvědčené postupy a nové oblasti výzkumu.

 


09/08/2015 03:41 PM
EMCDDA Hakkında

EMCDDA, Avrupa’da uyuşturucular hakkındaki referans noktanız

Avrupa Uyuşturucu ve Uyuşturucu Bağımlılığı İzleme Merkezi (EMCDDA) de 1993 yılında büyüyen uyuşturucu sorununa karşı bu esasla kurulmuştur. 1995 yılında Lizbon’da faaliyetlerine başlayan Merkez, AB’nin merkezileșmemiș kurumlarından biridir. EMCDDA, AB ve Üye Devletleri’ne Avrupa’nın uyuşturucu sorunlarına dair olgusal bir genel bakış ve uyuşturucu tartışmasını desteklemek üzere sağlam bir kanıt temeli sunmak üzere kurulmuştur. Bugün EMCDDA, politika yapıcılara uyuşturucu kanunları ve stratejileri oluşturmak için ihtiyaçları olan verileri sunmaktadır. Ayrıca uzmanlar ile bu alanda çalışan uygulayıcıların en iyi uygulamalar ile yeni araştırma alanları saptamalarına yardımcı olmaktadır.

 


09/08/2015 03:38 PM
O EMCDDA

EMCDDA, vaša referenčna točka za droge v Evropi

Evropski center za spremljanje drog in zasvojenosti z drogami (EMCDDA) je bil ustanovljen leta 1993. Slovesno je bil odprt v Lizboni leta 1995 in je ena od decentraliziranih agencij EU. Center EMCDDA zagotavlja EU in državam članicam dejanski pregled problematike drog v Evropi in obsežno zbirko izsledkov ter tako podpira razpravo o drogah. Oblikovalcem politike zagotavlja podatke, ki jih potrebujejo za sestavljanje utemeljenih zakonov in strategij za področje drog. Pomaga tudi strokovnjakom in osebam, ki delujejo na terenu, da določajo najboljše prakse in nova področja raziskovanja.


06/05/2015 04:00 PM
Countries

 


02/19/2015 09:53 AM
Publications

E-mail updates

Subscribe to receive the 'Just published' e-mail updates on new publications and products from the EMCDDA. 

Translating EMCDDA publications

To spread our publications to a wider audience, we encourage translations. More..

Citing EMCDDA publications

EMCDDA data and information can be reproduced and cited, provided that there is a clear indication of the source. More..

Coming up next

Find an overview of upcoming EMCDDA publications.

Ordering

Printed publications can be directly ordered from the EU Bookshop.

EU Bookshop

EMCDDA publications database

Our publications at your fingertips

Use the options below to search for publications of interest in our publications database. You can search by publication series, publication type, date published, and keywords. You can also use the search box to search for specific text.


06/21/2013 03:21 PM
Topics (A–Z)

 


05/31/2013 02:06 PM
.homePageHiddenItems

 


09/30/2011 08:47 AM
Home

 


01/10/2008 03:28 PM
.hiddenpages
Put here all the configuration element for this sites like left menu, site map ...